Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IPO Update: New Filings Feed Investor Fervor As Biopharma Stocks Rise

Executive Summary

IPO launches in the US hit a wall in August, but several biopharma firms recently entered the queue, adding new opportunities for investors to chase the industry's outperforming returns.

Advertisement

Related Content

Finance Watch: Roivant Raises $1.1bn, Relying On Private Equity To Fund New Companies
Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line
Finance Watch: Cash Flows Into Public Biopharmas, Including IPOs; Atlas Raises $350m VC Fund
Finance Watch: Bicycle Spins Toward Clinic With $52m Round; Stock Spikes Spur Offerings
Finance Watch: Surrozen Raises $33m In $483m February Flurry; Also, Are Reverse Mergers This Year's IPOs?
US IPOs In Review: Relatively Muted Market In 2016 To Continue In 2017
NightstaRx Boasts Advantage Over Spark In Inherited Retinal Disease
ProTide man Chris McGuigan hopes to make Nucana the next Gilead
BioNotebook: Three potential IPOs and a venture capital deal; Dermira, Rhythm, Syndax, OncoPep
NuCana raises $57m series B for pivotal PhIII cancer trials

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099454

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel